Current advancements and future perspectives of immunotherapy in colorectal cancer research

Kishore, Chandra; Bhadra, Priyanka

doi:10.1016/j.ejphar.2020.173819

Cited by 104 publications

(66 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most critical methods to indicate the early likelihood of CRC is the expansion of the tumor’s progression at the time of the diagnosis; depending on the invasion level of the tumor and the spread level to the regional lymph nodes, the prognosis can be worse [ 40 ]. Recently, studies aimed to identify possible molecular pathways involved in the progression and development of the pathogenesis of the disease to further enhance diagnostic and therapeutic modalities [ 41 ].…”

Section: Her4 Relationship To Different Cancersmentioning

confidence: 99%

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

et al. 2021

View full text Add to dashboard Cite

HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It is activated through ligand binding and activates MAPKs and PI3K/AKT pathways. HER4 is commonly expressed in many human tissues, both adult and fetal. It is important to understand the role of HER4 in the treatment of many disorders. Many studies were also conducted on the role of HER4 in tumors and its tumor suppressor function. Mostly, overexpression of HER4 kinase results in cancer development. In the present article, we reviewed the structure, location, ligands, physiological functions of HER4, and its relationship to different cancer types. HER4 inhibitors reported mainly from 2016 to the present were reviewed as well.

show abstract

Section: Her4 Relationship To Different Cancersmentioning

confidence: 99%

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…On the other side, immunotherapies, including T-cells reactive toward tumor associated antigens and immune checkpoint blockers, are other formats of targeted therapies, which have recently shown to effectively prolong survival rate of patients suffering from advanced metastatic cancers [ 13 , 14 ]. Nevertheless, low neoantigen burden of most cancer cells and insufficient infiltration of immune cells to the tumor site, have mostly restricted effectiveness of immunotherapies in clinic.…”

Section: Introductionmentioning

confidence: 99%

Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo

et al. 2021

View full text Add to dashboard Cite

Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells. Herein, using an engineered hypoxia responding nirB promoter, we developed an engineered Escherichia coli BW25133 strain capable of expressing cardiac peptides and GFP signaling protein under hypoxic condition for spatiotemporal targeting of mice mammary tumors. Following determination of the in vitro cytotoxicity profile of the engineered bacteria, selective accumulation of bacteria in tumor microenvironment was studied 48 h after tail vein injection of 108 cfu bacteria in animals. For in vivo evaluation of antitumoral activities, mice with establishment mammary tumors received 3 consecutive intravenous injections of transformed bacteria with 4-day intervals and alterations in expression of tumor growth, invasion and angiogenesis specific biomarkers (Ki-67, VEGFR, CD31and MMP9 respectively), as well as fold changes in concentration of proinflammatory cytokines were examined at the end of the 24-day study period. Intravenously injected bacteria could selectively accumulate in tumor site and temporally express GFP and cardiac peptides in response to hypoxia, enhancing survival rate of tumor bearing mice, suppressing tumor growth rate and expression of MMP-9, VEGFR2, CD31 and Ki67 biomarkers. Applied engineered bacteria could also significantly reduce concentrations of IL-1β, IL-6, GC-SF, IL-12 and TNF-α proinflammatory cytokines while increasing those of IL-10, IL-17A and INF-γ. Overall, administration of hypoxia-responding E. coli bacteria, carrying cardiac peptide expression construct could effectively suppress tumor growth, angiogenesis, invasion and metastasis and enhance overall survival of mice bearing mammary tumors.

show abstract

“…Introduction of checkpoint inhibitor (ICI) therapy provides remarkable achievements in multiple types of MSI-H or high tumor mutation burden(TMB-H) tumors. CRC patients with MSI-H have been well recognized as good candidates for ICI therapy [ 62 , 81 ]. In the study of Alvi et al [ 62 ], adaptive immunity (CD3) and the immune checkpoint (PD-L1) were tested through immunohistochemistry (IHC) to evaluate the adaptive immune resistance in 44 cases of colorectal SRCC.…”

Section: Tumor Immunology In Signet Ring Cell Carcinomamentioning

confidence: 99%

Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review

Zhou

Lin

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Colorectal signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC) with unique characteristics. Due to the limited researches on it, a comprehensive and in-depth understanding of this subtype is still lacking. In this article, we summarize the clinicopathological features and molecular characteristics of colorectal SRCC based on a literature review. Clinically, SRCC has been associated with young age, proximal site preference, advanced tumor stage, high histological grade, high rate of lymph node involvement, frequent peritoneal metastasis, and a significantly poor prognosis. Regarding molecular characteristics, in SRCC, the mutation burden of the classic signaling pathways that include WNT/β-catenin, RAS/RAF/MAPK, and PI3K/AKT/mTOR signaling pathways are generally reduced. In contrast, some genes related to the “epithelial-mesenchymal transition (EMT) process” and the “stem cell properties”, including RNF43, CDH1, and SMAD4, as well as the related TGF-β signaling pathway have been observed more frequently altered in SRCC than in conventional adenocarcinoma (AC). In many studies but not in others, SRCC showed a higher frequency of BRAF mutation, microsatellite instability-high (MSI-H) and CpG island methylator phenotype (CIMP) positive status compared to AC. It has been proposed that colorectal SRCC consists of two subtypes, in which the MSI+/CIMP+/BRAF+/CD3+/PD-L1+ hypermethylated genotype is more common in the proximal colon, and may represent the potential candidate for immunotherapy. Understanding the special molecular mechanisms related to the aggressive biology of SRCC is of great importance, which may provide a theoretical basis for the development of more targeted and effective treatments for this refractory disease.

show abstract

Current advancements and future perspectives of immunotherapy in colorectal cancer research

Cited by 104 publications

References 71 publications

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo

Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review

Contact Info

Product

Resources

About